Gilead faces lawsuit over HIV drug pricingGilead and other pharma companies stand accused of engaging in a scheme to block cheaper competitors to life-saving Share XGilead faces lawsuit over HIV drug pricinghttps://pharmaphorum.com/news/gilead-faces-lawsuit-over-hiv-drug-pricing/
Celgene-BMS merger looks good to go as shareholder backs downBristol-Myers Squibb’s mega-merger with Celgene looks set to go ahead after activist hedge fund Starboard Value backed out Share XCelgene-BMS merger looks good to go as shareholder backs downhttps://pharmaphorum.com/news/celgene-bms-merger-looks-good-to-go-as-shareholder-backs-down/
Celgene gets US patent let-off ahead of BMS mergerShares in Celgene ticked up yesterday after a let-off in a US court case challenging the patents on Share XCelgene gets US patent let-off ahead of BMS mergerhttps://pharmaphorum.com/news/celgene-gets-us-patent-let-off-ahead-of-bms-merger/
Oncology round-up: Shareholders question BMS/Celgene merger, while Merck & Co’s Keytruda keeps getting strongerWill it happen or not? There are doubts about whether the proposed $74 billion merger of cancer drug Share XOncology round-up: Shareholders question BMS/Celgene merger, while Merck & Co’s Keytruda keeps getting strongerhttps://pharmaphorum.com/views-analysis-oncology/oncology-round-up-shareholders-question-bms-celgene-merger-while-merck-cos-keytruda-keeps-getting-stronger/
Keytruda could get patient-friendly 6 week dosing schedule in EUUS-based Merck & Co is putting further pressure on its arch-rival Bristol-Myers Squibb with a potential new six-week Share XKeytruda could get patient-friendly 6 week dosing schedule in EUhttps://pharmaphorum.com/news/keytruda-could-get-patient-friendly-6-week-dosing-schedule-in-eu/
Largest BMS shareholder opposes Celgene dealBristol-Myers Squibb’s (BMS) largest shareholder has come out against the company’s planned merger with Celgene, putting the future Share XLargest BMS shareholder opposes Celgene dealhttps://pharmaphorum.com/news/largest-bms-shareholder-opposes-celgene-deal/
BMS looks to RNA splicing to boost immunotherapiesBristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and Share XBMS looks to RNA splicing to boost immunotherapieshttps://pharmaphorum.com/news/bms-looks-to-rna-splicing-to-boost-immunotherapies/
NHS funds BMS’ Opdivo to prevent skin cancer returningNICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer Share XNHS funds BMS’ Opdivo to prevent skin cancer returninghttps://pharmaphorum.com/news/nhs-funds-bms-opdivo-to-prevent-skin-cancer-returning/
EU approves Ipsen’s Cabometyx in second line liver cancerThe European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar. The Share XEU approves Ipsen’s Cabometyx in second line liver cancerhttps://pharmaphorum.com/news/european-commission-cabometyx/
